(Q34647657)

3 August 2017

1 reference

MDMA

0 references

title

Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk (English)

1 reference

3 August 2017

0 references

1 reference

1

Edmund Silins

1 reference

3 August 2017

Jan Copeland

2

1 reference

3 August 2017

Paul Dillon

series ordinal

3

1 reference

3 August 2017

publication date

1 August 2007

1 reference

Australian and New Zealand Journal of Psychiatry

3 August 2017

published in

1 reference

3 August 2017

volume

41

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

649-655

1 reference

Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Memory impairment in abstinent MDMA ("Ecstasy") users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Altered states: the clinical effects of Ecstasy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Ecstasy: are animal data consistent between species and can they translate to humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Death following ingestion of MDMA (ecstasy) and moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Ecstasy: pharmacodynamic and pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Recognition and management of complications of new recreational drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

A case of MAO inhibitor/MDMA interaction: agony after ecstasy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

21 January 2018

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Serotonin syndrome and other serotonergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

"Saturday night fever": ecstasy related problems in a London accident and emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Combining Stimulants With Monoamine Oxidase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Serotonergic mechanisms of cocaine effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Serotonin syndrome. Presentation of 2 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Safety of 5-hydroxy-L-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Possible interaction between an MAOI and "ecstasy"

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Ecstasy and the concomitant use of pharmaceuticals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Herbal medicines and perioperative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

21 January 2018

Herb-drug interactions

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Potential for interaction of kava and St. John's wort with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Mechanism of action of St John's wort in depression : what is known?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Hyperforin as a possible antidepressant component of hypericum extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Lisuride and LSD: Dopaminergic and serotonergic interactions in the ?serotonin syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The health effects of ecstasy: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Screening and intervention for illicit drug abuse: a national survey of primary care physicians and psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Alcohol abuse, other drug abuse, and mental disorders in medical practice. Prevalence, costs, recognition, and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Patterns of use and harm reduction practices of ecstasy users in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Club drugs, smart drugs, raves, and circuit parties: an overview of the club scene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Management of self poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670701449237

10.1080/00048670701449237

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference